THE 30-SECOND OVERVIEW
MOTS-c dosage research quick start
MOTS-c is one of the harder research peptides to write about honestly, because the gap between how often it is discussed and how much dosing data exists is wide. The published protocols are almost entirely rodent, given by injection, and aimed at metabolic questions. No human trial has established a dose.
Check the formulation
MOTS-c 10 mg vial. Other formats and blends may have different strengths.
Amount ≠ schedule
Concentration arithmetic does not determine dosing frequency or a safe human daily amount.
LABORATORY CONCENTRATION MATH
MOTS-c dosage calculator
Calculate the amount in a laboratory sample of the 10 mg MOTS-c vial. Enter the final solution volume, not the container capacity.
Enter positive volumes; the sample cannot exceed the final solution volume.
Illustrative arithmetic only. These inputs are not recommended preparation volumes or doses. This calculator does not recommend a route or schedule for human use.
What MOTS-c is
MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. It is a short peptide of 16 amino acids, and the unusual part is where it comes from: it is encoded in mitochondrial DNA rather than in the nuclear genome. Most peptides researchers work with are nuclear-encoded or synthetic analogues of nuclear-encoded hormones.
That origin is the reason MOTS-c gets attention. It belongs to a small group of mitochondrial-derived peptides, and the working hypothesis in the literature is that mitochondria use them to signal to the rest of the cell about their own state. MOTS-c has been studied mainly for effects on metabolic regulation, with AMPK activation as the pathway most often reported.
What the published protocols used
The foundational work is Lee and colleagues in Cell Metabolism, 2015, which characterised MOTS-c and reported effects on insulin sensitivity and diet-induced obesity in mice. Administration was by intraperitoneal injection, daily, over multiple weeks. Later work, including Reynolds and colleagues in Nature Communications, 2021, extended this to exercise capacity and again used injected MOTS-c in mice.
The numbers themselves: in the insulin-sensitivity work, Lee's mice received 5mg/kg of MOTS-c daily by intraperitoneal injection for seven days. In the high-fat-diet arm that prevented obesity, the dose was 0.5mg/kg daily for eight weeks.
Two things about those protocols matter more than the numbers.
First, they are expressed in milligrams per kilogram of body weight, which is standard for animal work and does not convert cleanly to a fixed human quantity. Allometric scaling between species is an estimate, not an equivalence, and the assumptions behind it are contested.
Second, the effects reported were dependent on repeated administration over weeks. These were not single-dose experiments. Any reading of the literature that treats MOTS-c as an acute intervention is not describing what the studies did.
Why there is no human dosing figure
Human MOTS-c research so far is largely observational rather than interventional. Studies have measured circulating MOTS-c and looked at how those levels associate with age, exercise, and metabolic status. That kind of work tells you about the peptide's behaviour as a biomarker. It does not tell you what quantity of exogenous MOTS-c produces an effect, because no exogenous MOTS-c was given.
This is the honest summary: any specific human figure circulating for MOTS-c is not sourced from a published trial. It comes from extrapolation, from vendor convention, or from user reports. Those are different things from evidence, and worth keeping separate.
Reconstitution and handling
MOTS-c is supplied lyophilised and needs reconstitution before use. The handling considerations are the ordinary ones for a short peptide, with no special instability of the kind tesamorelin has.
Introduce diluent slowly against the vial wall rather than directly onto the powder, and swirl instead of shaking. Agitation can denature peptides in solution. Keep the reconstituted solution cold and out of light, and treat it as having a shorter usable life than the lyophilised powder.
The arithmetic is where most errors happen. Concentration follows from how much diluent you add, so the same quantity of peptide in 1mL and in 2mL gives you solutions that differ twofold. A volume carried over from a differently reconstituted vial will be off by exactly that ratio. Recalculate rather than reuse, or run the numbers through our peptide calculator.
What the research does not establish
The species gap is the main limit. Rodent metabolic models are useful for mechanism and poor for predicting human dose response, and MOTS-c has not crossed that gap in the published record.
The route also differs from how it is often discussed. Published work used injection. Intranasal and oral routes, including the MOTS-c nasal spray format, have not been characterised for MOTS-c in the way injection has, so bioavailability by those routes is an open question rather than a known quantity.
And the pathway itself is broader than any single outcome. AMPK sits upstream of a lot of metabolic activity, which is why MOTS-c shows up in papers on several different endpoints. Reading one endpoint as the peptide's function overstates what is known.
The takeaway
MOTS-c dosing literature is rodent, injected, repeated over weeks, and expressed per kilogram. Research-grade MOTS-c for sale is stocked in both vial and nasal spray form. There is no established human protocol, and no published trial to convert those figures against. Researchers working with it are working ahead of the evidence, which is a legitimate position as long as it is stated plainly. Batch identity and purity for every lot we supply are published in our lab results.
All products are intended for research use only. Not for human consumption. Must be 21 years of age or older to purchase.
References
1. Lee, C., Zeng, J., Drew, B. G., et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 21(3), 443-454.
2. Reynolds, J. C., Lai, R. W., Woodhead, J. S. T., et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 12(1), 470.
